Successfully reported this slideshow.
Your SlideShare is downloading. ×

Claus Fuglsang - Novozymes - Denmark - Stanford Engineering - Jan 30 2012

Advertisement

More Related Content

Advertisement

More from Burton Lee

Advertisement

Claus Fuglsang - Novozymes - Denmark - Stanford Engineering - Jan 30 2012

  1. 1. Stanford Engineering, European Entrepreneurship & Innovation Claus Crone Fuglsang Managing Director January 30th 2012 Novozymes Inc.
  2. 2. A growing global population puts pressure on our natural resources. With bioinnovation in the form of, for example, industrial enzymes and microorganisms, industries can rethink their processes and products, and produce more with less. 2
  3. 3. Novozymes – The World Leader in Bioinnovation • Business consists of two segments: Enzyme Business and BioBusiness Founded 1941 • 2011 sales: USD ~ 2 billion Listed 2000 • 2011 EBIT margin: 22.3% Ticker NZYM B Exchange Copenhagen • More than 700 products used in 130 countries in over 40 different industries Market Cap* ~ 10 Billion USD • ~ 7,000 granted and pending patents • + 5,800 employees • Two share classes; A and B shares • A share capital and 11% of B shares (25.5% of O/S; 70.1% of votes) held by Enzyme Business BioBusiness Novo A/S, the management company of the Novo Nordisk Foundation Household Food & Feed & Micro- Bioenergy Biopharma Care Beverages other Tech. organisms *A+B shares January, 2012 3
  4. 4. Uniquely Diversified Group Creates Synergies and New Opportunities • Unique biotech-focused business with a strong legacy of delivering growth, earnings, and cash flow • ~ 14% of annual sales invested in R&D • Global provider of enzymes to all market segments creates global market leader position • Leveraging competencies across segments accelerates pace of innovation, reduces competition and creates high barriers to entry 31% 29% 17% 13% 7% 3% Household Food & Bioenergy Feed & other Micro- Biopharma Care Beverages Technical organisms enzymes • Laundry & • Baking • Corn ethanol • Animal feed • BioAgriculture • Drug delivery & Dishwasher • Brewing • Cellulosic • Textile • Wastewater formulation detergents • Starch to biofuels • Leather • Institutional • Medical devices syrups • Pulp & Paper & household • Wine & juice cleaning Enzyme Business BioBusiness 4
  5. 5. Diversification in Revenue Streams Underpins the Company’s Strong Financial Position • Enzymes account for 90% of turnover • Sales FY 2011 of DKK 10,510 billion (USD ~ 2 billion) • Strong profitability, ~ 22% in EBIT margin FY 2011 • ROIC of ~ 21% for FY 2011 2011 Sales by geography 2011 Sales by industry Biopharma Microorga 3% nisms Feed & 7% other Latin Tech. America enzymes 10% Europe, 13% Household Middle Asia Care East and Pacific enzymes Africa 19% 31% 36% Bioenergy enzymes 19% Food & North Beverages America enzymes 35% 29% 5
  6. 6. Undisputed Market Leader Expanding Enzyme Application Global enzyme market value: 2000: 2011: Global enzyme market value DKK ~ 12bn DKK ~ 20bn 2011: DKK ~ 20bn Novozymes Rest of Novozymes Rest of 47% Others and 42% market market 53% captive 58% 26% Novozymes 47% DSM 6% Market potential* Genencor Current enzyme market (DuPont) DKK ~ 20bn 21% Untapped market Multi-billion (US$) Rules of competition dictated by innovation *Global markets for chemicals, food ingredients, feed additives, etc. 6
  7. 7. R&D on the geographical map - 9 global competence centers / 1000 employees 105 employees 30 employees 553 employees  Strain dev.  Pharma center  All basic technologies  Bioinformatics  Albumin and  All application  Protein Engineering Albufusion technologies except  Protein Chemistry  Patent and regulatory textile  Biomass  Patent and regulatory 37 employees  Metabolic Engineering  Strain development  Patent  Protein Engineering  New applications  Regulatory 58 Employees  Strain discovery  Microbial physiology of mixed cultures  Microbial ecology  Microbe application expertise within technical microbes & BioAg 77 employees 66 employees  Fungal screening  Biofuel 27 employees  New applications  New Industries  Protein Engineering  Detergents  Renewal of chemicals  Protein Chemistry  Textiles 7employees  Application dev. W&J  Biomass  Patent and Regulatory  Biofuel  Surface fermentation  Patent and Regulatory
  8. 8. From gene-bank to product in 12 months Technologies Process Individual shuffling Family shuffling Creating Biological Nature’s diversity Diversity Bioinformatics Molecular evolution Mega libraries (int. and ext.) 1° Screening Protein Engineering Screening technology 2° Screening •High throughput screening: Microbial and Molecular level •Targeted assay Creating Expression Expression (bacterial, fungal) System Fermentation Up-scaling Process Purification Lab fermentation Pilot and tox material Production Formulation Full scale application test Biosolution based on Novozymes Technology
  9. 9. Novozymes, Inc Our key core technologies NZCA: today cover:  Established in 1992  Located in Davis, CA System Biology, Genomics &  45% males : 55 % females Bioinformatics  We have around 110 FTE Fungal & Bacterial Expression  Average seniority: 8 years Technology  Historically we file 12-25 Metabolic engineering patents/year Microbial Physiology & Fermentation Robotics, Assay Technology & HTS Protein Chemistry Artificial evolution
  10. 10. 10 Significant achievements CTec1 and CTec2 incl. discovery of GH61 Numerous improved production strains and molecular tools • Savinase, Polarzyme, Everlase, Pullulanase, Novamyl • Improved promoters, genomic loci for expression Genome sequencing and systems biology • Sequencing the genomes of more than 30 NZ organisms; host strains and BioAg strains incl. collaboration with JGI on T. reesei TV10 • Developed technology to identify specific nucleotide changes conferring improved yields in Bacillus strains Metabolic engineering • HA-strain development • CoRe projects established and running with 3 major partners: Cargill (3-HP), ADM, Braskem (Green PP)

×